Camblong Jurgi sold $286K of SOPH

Camblong Jurgi (Executive Chairman) sold 44,381 shares of SOPHiA GENETICS SA (SOPH) at an average of $6.45 ($6.17–$6.63, $0.29M total) across 3 trades over 2026-07-20 to 2026-07-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Camblong Jurgi
Published Jul 22, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The newest information is the specific sale size, execution dates, price range, and post-transaction holdings, which can influence short-term sentiment but typically has limited fundamental impact when tied to a 10b5-1 plan.

02

Market read

This is a routine insider-sale filing with disclosed transaction details; it is more relevant for sentiment monitoring than for a new fundamental thesis.

03

What to watch

Traders should check for any concurrent insider buys, additional Form 4 filings, or changes in guidance/financing that would make the sale more informative.

Relevance 3/10Novelty 4/10Timing: Filed on 2026-07-22 after-hours, reflecting sales executed 2026-07-20 to 2026-07-21.

Background

The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by executive chairman Camblong Jurgi.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

SEC Form 4 shows executive chairman Camblong Jurgi sold 44,381 SOPH shares for about $286.1K under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any price reaction should be small unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction with disclosed size, pricing range, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single, small insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than negative expectations.

Key entities

  • SOPHiA GENETICS SA

    Subject of the Form 4 insider transaction disclosure.

  • Camblong Jurgi

    Executive Chairman who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September